Relapsed and refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) are the focus of studies on hematological cancers. The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.